Abstract
Chronic hepatitis B virus (HBV) infection is a major global health problem. Current antiviral therapy including pegylated interferon and nucleos(t)ide analogue is effective in reducing progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma but the rate of HBsAg seroclearance is low. In this chapter, we review the barriers to eradicate HBV and how they may be overcome. We also discuss how cure of chronic HBV infection should be defined and measured and the likelihood that new antiviral and immune-modulatory drugs in development can achieve the goal of HBV cure.
| Original language | English |
|---|---|
| Title of host publication | Hepatitis B Virus and Liver Disease |
| Publisher | Springer Nature |
| Pages | 475-495 |
| Number of pages | 21 |
| ISBN (Electronic) | 9789811636158 |
| ISBN (Print) | 9789811636141 |
| DOIs | |
| State | Published - 23 08 2021 |
Bibliographical note
Publisher Copyright:© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2021. All rights reserved.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Covalently closed circular DNA
- Direct-acting antiviral agents
- Functional cure
- Hepatitis B surface antigen
- Immune modulatory therapies
Fingerprint
Dive into the research topics of 'Is cure of hepatitis B infection a mission possible?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver